Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Tenax Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Tenax Therapeutics, Inc.’s stock price such as:

• Tenax Therapeutics, Inc.’s current stock price and volume
• Why Tenax Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for TENX from analysts
• TENX’s stock price momentum as measured by its relative strength

About Tenax Therapeutics, Inc. (TENX)

Before we jump into Tenax Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Want to learn more about Tenax Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Tenax Therapeutics, Inc..

Tenax Therapeutics, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Tenax Therapeutics, Inc.’s stock price was $9.470.

Tenax Therapeutics, Inc. is up 0.74% from its previous closing price of $9.400.

During the last market session, Tenax Therapeutics, Inc.’s stock traded between $9.093 and $9.700. Currently, there are approximately 39.74 million shares outstanding for Tenax Therapeutics, Inc..

Tenax Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Tenax Therapeutics, Inc. Stock Price History

Tenax Therapeutics, Inc.’s (TENX) price is currently up 29.02% so far this month.

During the month of November, Tenax Therapeutics, Inc.’s stock price has reached a high of $9.700 and a low of $6.510.

Over the last year, Tenax Therapeutics, Inc. has hit prices as high as $9.700 and as low as $4.630. Year to date, Tenax Therapeutics, Inc.’s stock is up 52.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Tenax Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 26, 2025, there were 0 analysts who downgraded Tenax Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Tenax Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Tenax Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Tenax Therapeutics, Inc. (TENX) by visiting AAII Stock Evaluator.

Relative Price Strength of Tenax Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 26, 2025, Tenax Therapeutics, Inc. has a weighted four-quarter relative price strength of 22.27%, which translates to a Momentum Score of 92 and is considered to be Very Strong.

Want to learn more about how Tenax Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Tenax Therapeutics, Inc. Stock Price: Bottom Line

As of November 26, 2025, Tenax Therapeutics, Inc.’s stock price is $9.470, which is up 0.74% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Tenax Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.